三化汤治疗急性缺血性脑卒中28例

Observation on Treating Acute Ischemic Stroke for 28 Cases with SanHuaTang

目的:探讨三化汤治疗急性缺血性脑卒中的有效性和安全性。方法:收集本院2006年1月至2010年12月急性缺血性脑卒中患者58例,随机分为三化汤治疗组28例和西医对照组30例。用美国国立卫生院卒中量表(NIHSS)评分法比较治疗组与对照组的疗效差别,对比其总有效率、血液流变学指标变化情况。结果:治疗组患者神经功能缺损与用药前相比明显改善(P<0.05),且NIHSS评分改善优于对照组(P<0.05),2组治疗总有效率分别为89.3%与76.7%(P<0.05),治疗组血液流变学指标较对照组改善明显(P<0.05)。结论:三化汤可有效改善急性缺血性脑卒中患者的预后及血液流变学状况,用药安全性好,未出现明显不良反应。

Objective：To explore the efficacy and safety of SanHuaTang treating acute ischemic stroke.Method：58 patients with acute ischemic stroke were collected in hospital from January 2006 to December 2010,they were randomly assigned to two groups：the treatment group had 28 cases and the western medicine control group had 30 patients.NIHSS was used to compare the efficacy between the treatment group and the control group,compared the changes in total effective rate and hemorheology parameters.Result：The neurologic impairment of the treatment group significantly improved compared with before treatment（P0.05）,and the improvement was superior than the control group by NIHSS（P0.05）,the total effective rate of 2 groups were 89.3% and 76.7%（P0.05）,the treatment group had significant improvement than the control group in hemorheology parameters（P0.05）.Conclusion：SanHuaTang can effectively improve prognosis of patients with acute ischemic stroke and improve the status of hemorheology,it has goog safety,and no obvious adverse reactions.